Abstract：
Intravenous injectable metformin-Cu(II)-EGCG infinite coordination polymer nanoparticles (metformin-Cu(II)-EGCG ICP NPs) have been synthesized, and an efficient strategy for synergistic tumor therapy by utilizing these nanoparticles in conjunction with micro-electrothermal needles (MENs) was proposed. These nanoparticles display exceptional uniformity with a diameter of 117.5 ± 53.3 nm, exhibit an extraordinary drug loading capacity of 90% and allow for precise control over the drug ratio within the range of 1 : 1 to 1 : 20 while maintaining excellent thermal stability. Fourier transform infrared spectroscopy, X-ray photoelectron spectroscopy, and X-ray diffraction were employed to determine their chemical structure and coordination state. The combination index (CI) value of the metformin-Cu(II)-EGCG ICP NPs was calculated to be 0.19, surpassing that of the two individual drugs and metformin mixed with EGCG (0.98). Importantly, upon intravenous injection, metformin in nanoparticles demonstrated exceptional stability in the bloodstream, while both drugs were rapidly released within the acidic tumor microenvironment. Animal experiments showcased an impressive tumor inhibition rate of 100% within a mere 20-day time frame after the synergistic therapy with a lower dosage (5.0 mg kg-1 of nanoparticles), coupled with a minimal tumor recurrence rate of only 18.75% over a 60-day observation period. These findings indicate the promising prospects of these nanoparticles in tumor treatment.
摘要：
已合成静脉可注射的二甲双胍-Cu（II）-EGCG无限配位聚合物纳米颗粒（二甲双胍-Cu（II）-EGCGICPNPs），并提出了通过利用这些纳米颗粒与微电热针（MENs）联合进行协同肿瘤治疗的有效策略。这些纳米颗粒显示出优异的均匀性，直径为117.5±53.3nm，表现出90%的非凡的药物负载能力,并且允许在1:1至1:20的范围内精确控制药物比例,同时保持优异的热稳定性。傅里叶变换红外光谱,X射线光电子能谱,和X射线衍射来确定它们的化学结构和配位状态。二甲双胍-Cu（II）-EGCGICPNP的组合指数（CI）值计算为0.19，超过两种单独药物和二甲双胍与EGCG混合的组合指数（0.98）。重要的是,静脉注射后，二甲双胍纳米颗粒在血液中表现出非凡的稳定性，而两种药物在酸性肿瘤微环境中迅速释放。动物实验显示，在较低剂量（5.0mgkg-1纳米颗粒）的协同治疗后，仅20天的时间范围内，肿瘤抑制率达到了100％，令人印象深刻。再加上在60天的观察期内，肿瘤的最小复发率仅为18.75%。这些发现表明了这些纳米颗粒在肿瘤治疗中的有希望的前景。
